About GPI ethanolamine phosphate transferase, stabilizing subunit
GPI ethanolamine phosphate transferase, stabilizing subunit (PIGF) is a protein
from Homo sapiens identified by UniProt accession
Q07326, 219 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | GPI ethanolamine phosphate transferase, stabilizing subunit |
|---|
| UniProt accession | Q07326 |
|---|
| Gene | PIGF |
|---|
| Organism | Homo sapiens |
|---|
| Length | 219 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (30)
Diseases linked to this target (Open Targets).
- onychodystrophy, osteodystrophy, impaired intellectual development, and seizures syndrome · score 0.45
- neurodegenerative disease · score 0.36
- Rothmund-Thomson syndrome, type 3 · score 0.34
- brain volume measurement · score 0.29
- brain measurement · score 0.27
- neuroimaging measurement · score 0.27
- gait measurement · score 0.20
- chronotype measurement · score 0.11
- sitting height measurement · score 0.07
- red blood cell density measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q07326-F1 | alphafold | PREDICTED | 92.74 | — |
Amino-acid sequence (219 residues)
MKDNDIKRLL YTHLLCIFSI ILSVFIPSLF LENFSILETH LTWLCICSGF VTAVNLVLYL VVKPNTSSKR SSLSHKVTGF LKCCIYFLMS CFSFHVIFVL YGAPLIELAL ETFLFAVILS TFTTVPCLCL LGPNLKAWLR VFSRNGVTSI WENSLQITTI SSFVGAWLGA LPIPLDWERP WQVWPISCTL GATFGYVAGL VISPLWIYWN RKQLTYKNN
Explore GPI ethanolamine phosphate transferase, stabilizing subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets